Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 10/20 | 0.81 |
| ▸ | FNTA | P49354 | 6/20 | 0.33 |
| ▸ | FNTB | P49356 | 6/20 | 0.33 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.32 |
| ▸ | CNR1 | P21554 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4919387 | 0.91 | AR (0.81) | ARPTGDR2CYP11B2CNR1 | |
| SCHEMBL4921936 | 0.90 | AR (1.00) | ARFNTAFNTBPTGDR2CYP11B2 | |
| SCHEMBL14114850 | 0.87 | AR (0.87) | ARFNTAFNTBPTGDR2CYP11B2 | |
| SCHEMBL4921463 | 0.85 | AR (0.81) | ARFNTAFNTBPTGDR2CNR1 | |
| SCHEMBL4914410 | 0.85 | AR (0.84) | ARCYP11B2CNR1 | |
| SCHEMBL4918903 | 0.84 | AR (0.82) | ARFNTAFNTBPTGDR2CYP11B2 | |
| SCHEMBL4922214 | 0.84 | AR (0.89) | ARFNTAFNTBPTGDR2CNR1 | |
| SCHEMBL4919567 | 0.84 | AR (0.82) | ARFNTAFNTBPTGDR2CYP11B2 | |
| SCHEMBL4915218 | 0.84 | AR (0.82) | ARFNTAFNTBPTGDR2CYP11B2 | |
| SCHEMBL4920911 | 0.84 | AR (0.81) | ARFNTAFNTBCYP11B2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080176906-A1 | Substituted Pyrrole Derivative | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-07-24 | — | — | US | disclosed |
| US-20080176906-A1 | Substituted Pyrrole Derivative | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-07-24 | — | — | US | disclosed |
| US-20080176906-A1 | Substituted Pyrrole Derivative | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-07-24 | — | — | US | disclosed |
| EP-1824841-A1 | SUBSTITUTED PYRROLE DERIVATIVE | Takeda Pharmaceutical Company Limited (JP) | 2007-08-29 | — | — | EP | disclosed |
| WO-2006064944-A1 | SUBSTITUTED PYRROLE DERIVATIVE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176906-A1 | Substituted Pyrrole Derivative | AR, NR5A1, MC2R | AR 1/4885FNTA 4295/4885FNTB 4695/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.